US Stock MarketDetailed Quotes

CVKD Cadrenal Therapeutics

Watchlist
  • 15.750
  • +0.330+2.14%
Trading Mar 11 09:49 ET
28.07MMarket Cap-2.56P/E (TTM)

About Cadrenal Therapeutics Company

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Company Profile

SymbolCVKD
Company NameCadrenal Therapeutics
Listing DateJan 20, 2023
Issue Price5.00
Founded2022
CEOMr. Quang X. Pham
MarketNASDAQ
Employees4
Fiscal Year Ends12-31
Address822 A1A North,Suite 306
CityPonte Vedra Beach
ProvinceFlorida
CountryUnited States of America
Zip Code32082
Phone1-904-300-0701
Websitehttp://www.cadrenal.com

Company Executives

  • Name
  • Position
  • Salary
  • Quang X. Pham
  • Chairman of the Board and Chief Executive Officer
  • 967.00K
  • Dr. James J. Ferguson, III,M.D.
  • Chief Medical Officer
  • --
  • Jeffrey Cole
  • Chief Operating Officer
  • --
  • Matthew K. Szot
  • Chief Financial Officer and Principal Accounting Officer
  • 844.89K
  • John Raymond Murphy
  • Independent Director
  • 50.00K
  • Steven Zelenkofske
  • Independent Director
  • 35.00K
  • Robert Lisicki
  • Independent Director
  • 74.50K
  • Dr. Glynn Wilson,PhD
  • Independent Director
  • 35.00K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
Hanshow Technology
301275
+143.35%
Yong Jie New Material
603271
+124.42%
ZZT
873726
+29.99%
4
BEOKA
870199
+23.76%
5
Geovis Insighter Technology
920116
+21.91%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More
TSLA earnings preview: Grab rewards by guessing the opening price!